Galecto (GLTO) Competitors $3.25 -0.04 (-1.09%) As of 08/1/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GLTO vs. PRPH, ABP, LEXX, SYBX, LPCN, CASI, BLRX, ATNF, GELS, and ATHAShould you be buying Galecto stock or one of its competitors? The main competitors of Galecto include ProPhase Labs (PRPH), Abpro (ABP), Lexaria Bioscience (LEXX), Synlogic (SYBX), Lipocine (LPCN), CASI Pharmaceuticals (CASI), BioLineRx (BLRX), 180 Life Sciences (ATNF), Gelteq (GELS), and Athira Pharma (ATHA). These companies are all part of the "pharmaceutical products" industry. Galecto vs. Its Competitors ProPhase Labs Abpro Lexaria Bioscience Synlogic Lipocine CASI Pharmaceuticals BioLineRx 180 Life Sciences Gelteq Athira Pharma ProPhase Labs (NASDAQ:PRPH) and Galecto (NASDAQ:GLTO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends. Is PRPH or GLTO more profitable? Galecto's return on equity of -98.27% beat ProPhase Labs' return on equity.Company Net Margins Return on Equity Return on Assets ProPhase LabsN/A -184.38% -64.59% Galecto N/A -98.27%-84.29% Which has more risk & volatility, PRPH or GLTO? ProPhase Labs has a beta of -0.41, indicating that its stock price is 141% less volatile than the S&P 500. Comparatively, Galecto has a beta of 1.35, indicating that its stock price is 35% more volatile than the S&P 500. Do institutionals and insiders hold more shares of PRPH or GLTO? 9.4% of ProPhase Labs shares are held by institutional investors. Comparatively, 14.2% of Galecto shares are held by institutional investors. 9.6% of ProPhase Labs shares are held by insiders. Comparatively, 10.8% of Galecto shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Do analysts prefer PRPH or GLTO? Galecto has a consensus target price of $10.00, indicating a potential upside of 210.08%. Given Galecto's stronger consensus rating and higher possible upside, analysts plainly believe Galecto is more favorable than ProPhase Labs.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ProPhase Labs 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Galecto 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better earnings & valuation, PRPH or GLTO? Galecto has lower revenue, but higher earnings than ProPhase Labs. ProPhase Labs is trading at a lower price-to-earnings ratio than Galecto, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProPhase Labs$5.85M2.32-$53.36M-$1.26-0.26GalectoN/AN/A-$21.44M-$15.53-0.21 Does the media prefer PRPH or GLTO? In the previous week, ProPhase Labs and ProPhase Labs both had 1 articles in the media. ProPhase Labs' average media sentiment score of 0.00 equaled Galecto'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProPhase Labs 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Galecto 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryGalecto beats ProPhase Labs on 9 of the 12 factors compared between the two stocks. Get Galecto News Delivered to You Automatically Sign up to receive the latest news and ratings for GLTO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GLTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GLTO vs. The Competition Export to ExcelMetricGalectoMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.35M$3.00B$5.49B$9.52BDividend YieldN/A2.43%4.73%4.09%P/E Ratio-0.2117.6228.7823.81Price / SalesN/A179.21372.2066.04Price / CashN/A41.9535.4557.96Price / Book0.298.508.275.54Net Income-$21.44M-$55.06M$3.25B$259.28M7 Day Performance-14.00%-3.99%-3.70%-4.64%1 Month Performance-7.33%9.58%4.34%4.41%1 Year Performance-75.38%6.70%25.90%17.95% Galecto Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GLTOGalecto2.3469 of 5 stars$3.23-2.0%$10.00+210.1%-76.6%$4.35MN/A-0.2140News CoveragePRPHProPhase Labs0.6315 of 5 stars$0.44-4.7%N/A-89.1%$19.36M$6.77M-0.35130Gap DownABPAbproN/A$0.32+1.3%$4.00+1,152.0%N/A$19.17M$180K0.0015Gap DownHigh Trading VolumeLEXXLexaria Bioscience2.7019 of 5 stars$0.90-8.5%$5.00+458.7%-78.6%$19.13M$460K-1.347News CoverageAnalyst ForecastAnalyst RevisionGap DownHigh Trading VolumeSYBXSynlogic1.0261 of 5 stars$1.62+1.9%N/A-14.0%$18.60M$10K-0.6580Positive NewsUpcoming EarningsLPCNLipocine2.6247 of 5 stars$3.33-3.2%$9.00+170.2%-38.0%$18.41M$11.20M-3.2710Positive NewsUpcoming EarningsCASICASI Pharmaceuticals3.9515 of 5 stars$1.62+9.5%$4.00+146.9%-81.7%$18.20M$28.54M-0.64180Positive NewsGap UpBLRXBioLineRx2.0932 of 5 stars$4.16-2.1%$26.00+525.0%-86.1%$18.12M$28.94M-0.4740Gap DownATNF180 Life Sciences0.6218 of 5 stars$2.91-3.0%N/A+68.6%$18.12MN/A-0.197News CoverageAnalyst ForecastGap DownGELSGelteqN/A$1.83-4.2%N/AN/A$18.03MN/A0.00N/AATHAAthira Pharma3.2455 of 5 stars$0.41-9.9%$11.25+2,625.3%-88.6%$17.88MN/A-0.2040News CoverageUpcoming EarningsGap Down Related Companies and Tools Related Companies ProPhase Labs Competitors Abpro Competitors Lexaria Bioscience Competitors Synlogic Competitors Lipocine Competitors CASI Pharmaceuticals Competitors BioLineRx Competitors 180 Life Sciences Competitors Gelteq Competitors Athira Pharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GLTO) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galecto, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galecto With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
